Literature DB >> 1325087

The pathobiology of salivary gland. II. Morphological evaluation of acinic cell carcinomas in the parotid gland of male transgenic (MMTV/v-Ha-ras) mice as a model for human tumours.

I Dardick1, A P Burford-Mason, D S Garlick, W P Carney.   

Abstract

In the transgenic TG.SH (mouse mammary tumour virus/v-Ha-ras) mouse, designed to develop mammary tumours, occasional spontaneous salivary gland tumours have been reported, predominantly in males. The incidence and histomorphology of salivary gland tumours in 73 TG.SH mice were surveyed and in total, 21.9% developed both overt and microscopic parotid tumours. The majority developed between 73 and 150 days of age. In 31.5% of the TG.SH mice, occasional unilateral, but more frequently bilateral exophthalmos due to hyperplasia of the intraorbital (Harderian) lacrimal gland was observed. In 70% of these animals, parotid tumours developed later. Since Harderian gland hyperplasia, occurring as early as 5 weeks of age, preceded the development of palpable salivary gland lesions, this stigma is useful for the early selection of animals likely to progress to tumour formation. Before tumour-bearing transgenic mice are considered to be suitable models of human neoplastic disease, morphological characterization is necessary to ensure that the tumours are histologically representative of the human lesions for which they are potential models. In this study, all parotid tumours consisted of acinar-like glandular structures with central lumina discernible by electron microscopy. Ultrastructurally, secretory granules evident in the apical cytoplasm of the tumour cells resembled the zymogen granules of the normal parotid acinar cell, and some cells had a prominent complement of rough endoplasmic reticulum. These features, along with focal amylase expression detected immunohistochemically in some parotid tumours, identified these neoplasms as acinic cell carcinomas that mimic the human salivary gland acinic cell carcinoma faithfully.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325087     DOI: 10.1007/bf01607042

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  19 in total

1.  Morphogenesis of salivary gland tumors. A prerequisite to improving classification.

Authors:  I Dardick; A W van Nostrand
Journal:  Pathol Annu       Date:  1987

Review 2.  Transgenic mice--a gold mine for furthering knowledge in pathobiology.

Authors:  R A Cuthbertson; G K Klintworth
Journal:  Lab Invest       Date:  1988-05       Impact factor: 5.662

3.  Expression of the ERBB2 protein in benign and malignant salivary gland tumors.

Authors:  G Stenman; J Sandros; A Nordkvist; J Mark; P Sahlin
Journal:  Genes Chromosomes Cancer       Date:  1991-03       Impact factor: 5.006

Review 4.  The controversy of Warthin's tumor.

Authors:  J S Chapnik
Journal:  Laryngoscope       Date:  1983-06       Impact factor: 3.325

Review 5.  Animal models of human disease. Pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carrying and expressing activated cellular oncogenes.

Authors:  P K Pattengale; T A Stewart; A Leder; E Sinn; W Muller; I Tepler; E Schmidt; P Leder
Journal:  Am J Pathol       Date:  1989-07       Impact factor: 4.307

6.  A salivary amylase transgene is efficiently expressed in liver but not in parotid gland of transgenic mice.

Authors:  J M Jones; S A Keller; L C Samuelson; L Osborn; M P Rosenberg; M H Meisler
Journal:  Nucleic Acids Res       Date:  1989-08-25       Impact factor: 16.971

7.  Multiple transcriptional activation of cellular oncogenes in human head and neck solid tumours.

Authors:  D A Spandidos; A Lamothe; J K Field
Journal:  Anticancer Res       Date:  1985 Mar-Apr       Impact factor: 2.480

8.  Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity, hormonal regulation, and tumor induction in transgenic mice.

Authors:  A C Andres; C A Schönenberger; B Groner; L Hennighausen; M LeMeur; P Gerlinger
Journal:  Proc Natl Acad Sci U S A       Date:  1987-03       Impact factor: 11.205

9.  Cellular proliferation and ras oncogene of p21 21,000 expression in relation to the intracellular cyclic adenosine 3':5'-monophosphate levels of a human salivary gland adenocarcinoma cell line in culture.

Authors:  M Azuma; H Yoshida; H Kawamata; T Yanagawa; N Furumoto; M Sato
Journal:  Cancer Res       Date:  1988-05-15       Impact factor: 12.701

10.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.

Authors:  W J Muller; E Sinn; P K Pattengale; R Wallace; P Leder
Journal:  Cell       Date:  1988-07-01       Impact factor: 41.582

View more
  5 in total

Review 1.  Salivary acinic cell carcinoma: reappraisal and update.

Authors:  V Vander Poorten; A Triantafyllou; L D R Thompson; J Bishop; E Hauben; J Hunt; A Skalova; G Stenman; R P Takes; D R Gnepp; H Hellquist; B Wenig; D Bell; A Rinaldo; A Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-12-19       Impact factor: 2.503

Review 2.  Salivary gland tumor: a review of 599 cases in a Brazilian population.

Authors:  Flávia Aparecida de Oliveira; Eliza Carla Barroso Duarte; Cláudia Teixeira Taveira; Aline Abreu Máximo; Erica Carvalho de Aquino; Rita de Cássia Alencar; Eneida Franco Vencio
Journal:  Head Neck Pathol       Date:  2009-09-16

3.  Rapid development of salivary gland carcinomas upon conditional expression of K-ras driven by the cytokeratin 5 promoter.

Authors:  Ana R Raimondi; Lynn Vitale-Cross; Panomwat Amornphimoltham; J Silvio Gutkind; Alfredo Molinolo
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

4.  A hypothesis to relate salivary tumors with mammary and prostate neoplasias.

Authors:  Adriana B Actis
Journal:  Bioinformation       Date:  2005-04-21

5.  [Epidemiologic profile of salivary gland neoplasms: analysis of 245 cases].

Authors:  Solange Souza Lima; Andréa Ferreira Soares; Rivadávio Fernandes Batista de Amorim; Roseana de Almeida Freitas
Journal:  Braz J Otorhinolaryngol       Date:  2005-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.